5-乙基-5-(仲-戊基)巴比妥酸钙盐 | 7563-42-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-乙基-5-(仲-戊基)巴比妥酸钙盐
• CAS: 7563-42-0
• 化学式: C11H18CaN2O3
• 分子量: 266.35
• InChiKey: ZZICGYMWXSMNIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  75.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  6.1(b)
• 包装等级：
  III
• 危险类别：
  6.1(b)

制备方法与用途

类别

有毒物质

毒性分级

高毒

急性毒性

口服-狗 LDL0: 60 毫克/公斤; 静脉-狗 LDL0: 70 毫克/公斤

可燃性危险特性

热分解排出有毒氮氧化物烟雾

储运特性

库房低温通风干燥; 与食品原料分开存放

灭火剂

水, 二氧化碳, 泡沫, 干粉

文献信息

• [EN] 18F-LABELLED BARBITURATE COMPOUNDS FOR USE AS POSITRON EMISSION IMAGING AGENTS<br/>[FR] COMPOSÉS BARBITURIQUES MARQUÉS AU 18F, CONVENANT COMME AGENTS D'IMAGERIE PAR ÉMISSION DE POSITRONS
  申请人：UNIV ABERDEEN

  公开号：WO2013038153A1

  公开（公告）日：2013-03-21

  The present invention relates generally to the field of diagnostic methods. More specifically, the present invention pertains to certain 18F-labelled barbiturate compounds of the following formula (collectively referred to herein as "18F-fluorinated barbiturate compounds" and "18FBAR compounds") that bind to metals, for example, metals associated with protein aggregates, and as such are useful as imaging agents for positron emission imaging (e.g., positron emission tomography (PET) imaging) used in the diagnosis and monitoring of conditions involving these aggregates, including Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). These compounds also bind strongly to GABAA receptors and hence are also useful as imaging agents for positron emission tomography (PET) imaging used in the diagnosis, monitoring and study of diseases involving dis-regulation of these receptors, including epilepsy, schizophrenia, and mood disorders (e.g., anxiety).

  本发明通常涉及诊断方法领域。更具体地说，本发明涉及以下化学式的某些18F标记的巴比妥化合物（以下统称为“18F氟代巴比妥化合物”和“18FBAR化合物”），这些化合物结合到金属，例如与蛋白聚集物相关的金属，并因此可用作正电子发射成像（例如正电子发射断层扫描（PET）成像）的成像剂，用于诊断和监测涉及这些聚集物的疾病，包括阿尔茨海默病（AD）、帕金森病（PD）和亨廷顿病（HD）。这些化合物还强烈结合到GABAA受体，因此也可用作正电子发射断层扫描（PET）成像的成像剂，用于诊断、监测和研究涉及这些受体失调的疾病，包括癫痫、精神分裂症和情绪障碍（例如焦虑）。
• Pharmaceutical compositions for prevention of overdose or abuse
  申请人：Mickle Travis

  公开号：US20060014697A1

  公开（公告）日：2006-01-19

  The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause overdose or to be abused. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent.

  本发明涉及制药组合物，其中化学基团连接到活性剂上，以大大降低活性剂引起过量或被滥用的潜力。当以适当剂量给予时，该制药组合物提供与母体活性剂类似的治疗活性。
• PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OF OVERDOSE OR ABUSE
  申请人：MICKLE TRAVIS

  公开号：US20110046226A1

  公开（公告）日：2011-02-24

  The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause overdose or to be abused. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent.

  本发明涉及药物组合物，其中化学基团与活性成分以一种方式连接，从而大大降低了活性成分引起过量或被滥用的潜力。当以适当剂量给药时，该药物组合物提供与原始活性成分类似的治疗活性。
• Adhesive device for transdermal administration of an active agent
  申请人：NITTO DENKO CORPORATION

  公开号：EP0452837A2

  公开（公告）日：1991-10-23

  A medical adhesive comprising a plaster layer containing the following ingredients, characterized in that the ingredient ② is incorporated in a larger amount than the ingredient ⑤ and in an amount not less than 25% by weight relative to the total amount of the ingredients ①∼⑤, and the plaster layer is a W/O type : ① a medicinal ingredient, ② a hydrophobic polymer having a glass transition temperature (Tg) of -65°C to 35°C, ③ a percutaneous absorption-promoting agent, ④ water, and ⑤ a hydrophilic polymer which is soluble or capable of swelling in water; and a medical adhesive which comprises a porous base layer in the plaster layer or in contact with the plaster layer, which enable stable release of the medicinal ingredient, the percutaneous absorption-promoting agents and so on and sustaining of the pharmacological effects over a long period.

  一种医用粘合剂，由含有下列成分的石膏层组成，其特征在于，成分②的掺入量大于成分⑤，且相对于成分①∼⑤的总掺入量不低于 25%（重量百分比），石膏层为 W/O 型： 药物成分、 一种疏水性聚合物，其玻璃转化温度（Tg）为-65°C 至 35°C、 经皮吸收促进剂、 水，以及 可溶于水或能在水中溶胀的亲水性聚合物；以及 一种医用粘合剂，由石膏层中的多孔基底层或与石膏层接触的多孔基底层组成，可使药物成分、促进经皮吸收剂等稳定释放，并长期保持药理作用。
• INHIBITOR FOR PERIOPERATIVE BLOOD SUGAR ELEVATION
  申请人：OTSUKA PHARMACEUTICAL FACTORY, INC.

  公开号：EP1591116A1

  公开（公告）日：2005-11-02

  An inhibitor for perioperative blood sugar elevation characterized by containing a branched amino acid, a compound which can be converted into a branched amino acid in vivo or a compound to which an amino group has been transferred from a branched amino acid. This inhibitor for perioperative blood sugar elevation is useful as a drug which is safe to the living body including human, inhibits abnormal elevation in the blood glucose level caused by anesthesia, surgery, etc. , and enables proper blood sugar control, when administered to a perioperative patient.

  一种围手术期血糖升高抑制剂，其特征在于含有支链氨基酸、可在体内转化为支链氨基酸的化合物或从支链氨基酸转移了氨基的化合物。这种围手术期血糖升高抑制剂作为一种对包括人体在内的活体安全的药物，可抑制因麻醉、手术等引起的血糖水平异常升高，使血糖得到适当的控制，从而发挥其作用。这种围术期血糖升高抑制剂作为一种对包括人体在内的活体安全的药物，在对围术期病人用药时，可抑制因麻醉、手术等引起的血糖水平异常升高，使血糖得到适当控制。